FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

All told, 89% of those on Lilly's drug achieved a 5% body weight reduction, versus 28% of the placebo arm, with 55% and 1.3% respectively achieving a 20% reduction. "Tirzepatide is the first ...

Novo conducted a Phase IIIb trial dubbed STRIDE to evaluate the effects of a 1 mg dose of semaglutide versus placebo in patients ... to-head comparison of Zepbound (tirzepatide) against its older ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant increase in pancreatitis risk despite elevating pancreatic enzyme levels, ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

more equivalent oral dose of tirzepatide, based on conventional oral versus injectable semaglutide dosing, has still unknown potential to be investigated relative to injected Zepbound®.

Playing their first match of 2025, the United States Men's National Soccer Team defeated Venezuela 3-1 in an international friendly at Chase Stadium in Fort Lauderdale, Florida, on Saturday ...